Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry ( RegCOVID19 )

Study identification

• EU PAS number:
  EUPAS34551
• Study ID:
  41029
• Official title and acronym:
  Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry ( RegCOVID19 )
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  The infection caused by COVID19 worldwide makes it necessary to monitor drugs administered for the treatment of patients hospitalized with SARSCoV-2. In order to know more about the efficacy and safety of the treatments used, researchers from the Cantabrian health service have developed an multi-center observational study, in the form of an ambispective registry, in which clinical data from patients treated with the different drugs currently recommended by the Spanish Agency of Medicines and Health Products (SAMHP) and the Ministry of Health, or others that may arise, are collected and analyzed. Although the conduct of clinical trials is a priority at this time, we cannot lose the clinical experience that is currently being generated, which may allow us to improve the therapeutic strategies for future patients.
• Study status:
  Planned

Research institutions and networks

Institutions

Instituto de Investigación Sanitaria Valdecilla (IDIVAL)

Study timelines

Date when funding contract was signed

Planned:06/04/2020

Study start date

Planned:10/04/2020

Data analysis start date

Planned:24/04/2020

Date of interim report, if expected

Planned:08/05/2020

Date of final study report

Planned:30/09/2021

Sources of funding

Other

More details on funding

Own funds

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable